Edition:
India

Aralez Pharmaceuticals Inc (ARLZ.OQ)

ARLZ.OQ on NASDAQ Stock Exchange Global Select Market

1.43USD
8:42pm IST
Change (% chg)

$-0.01 (-0.69%)
Prev Close
$1.44
Open
$1.41
Day's High
$1.50
Day's Low
$1.40
Volume
23,910
Avg. Vol
119,371
52-wk High
$5.04
52-wk Low
$0.95

Latest Key Developments (Source: Significant Developments)

Aralez Announces Departure Of Chief Financial Officer
Friday, 1 Dec 2017 

Nov 30 (Reuters) - Aralez Pharmaceuticals Inc ::ARALEZ ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍SCOTT J. CHARLES, CHIEF FINANCIAL OFFICER, IS LEAVING COMPANY​.ARALEZ PHARMACEUTICALS INC - MICHAEL KASETA WILL ASSUME POSITION OF INTERIM CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍ PRIOR TO JOINING ARALEZ, KASETA SERVED AS CFO OF SANOFI NORTH AMERICA, GLOBAL SERVICES​.  Full Article

Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®.LANNETT COMPANY INC - FINANCIAL TERMS WERE NOT DISCLOSED..LANNETT COMPANY INC - HAS ENTERED INTO AN AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC.LANNETT COMPANY - ‍AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF AUTHORIZED GENERIC VERSION OF TOPROL-XL​.LANNETT COMPANY INC - DEAL TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF TOPROL-XL EXTENDED RELEASE TABLETS IN 25 MG, 50 MG, 100 MG AND 200MG.  Full Article

Aralez Pharmaceuticals files for mixed shelf offering of up to $100 mln - SEC filing‍​
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez Pharmaceuticals Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​.  Full Article

Aralez sees 2018 net revenues $140 mln to $160 mln‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez announces third quarter 2017 financial results and achieves profitability on an adjusted EBITDA basis for the first time in the third quarter.Aralez Pharmaceuticals Inc - ‍provides updated 2017 full-year guidance and preliminary 2018 full-year outlook​.Aralez Pharmaceuticals Inc - ‍plans to implement further financial improvements designed to streamline U.S. business​.Aralez Pharmaceuticals Inc - ‍net loss in Q3 of 2017 was $24.4 million, or $0.37 per diluted share​.Qtrly total revenues, net $24.3 million versus $13.6 mln‍​.Aralez Pharmaceuticals Inc - ‍updated 2017 net revenues to be in a range of $95 million to $105 million​.Aralez Pharmaceuticals Inc - sees 2018 net revenues $140 million to $160 million‍​.  Full Article

Aralez Q2 GAAP loss per share $0.27
Tuesday, 9 Aug 2016 

Aralez Pharmaceuticals Inc : Aralez reports second quarter 2016 financial results . Q2 revenue $12.6 million versus $5.2 million . Q2 GAAP loss per share $0.27 .Q2 earnings per share view $-0.22, revenue view $11.9 million -- Thomson Reuters I/B/E/S.  Full Article

Aralez posts Q1 loss of $0.73/share
Tuesday, 10 May 2016 

Aralez Pharmaceuticals Inc : Aralez reports first quarter 2016 financial results . Qtrly GAAP loss per share $0.73 .Total net revenues for three months ended March 31, 2016 were about $8.1 million compared to $4.4 million.  Full Article

Aralez Pharmaceuticals receives Health Canada approval For BLEXTEN
Monday, 25 Apr 2016 

Aralez Pharmaceuticals:Says Health Canada approval of BLEXTEN for treatment of symptoms of seasonal allergic rhinitis and chronic spontaneous urticaria.BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc, also a subsidiary of Company.  Full Article

BRIEF-Aralez Pharmaceuticals files for mixed shelf offering of up to $100 mln - SEC filing‍​

* Aralez Pharmaceuticals Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​ Source text: (http://bit.ly/2zrTHPn) Further company coverage: